Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVC1-0101 intramuscular injection for peripheral arterial disease with intermittent claudication or critical limb ischaemia
ACTRN12615001144505Phase 2Terminated
- Sponsor
- CMAX Clinical Research
- Start
- Nov 2016
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of DVC1-0101 in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI) (4 arms), sponsored by CMAX Clinical Research. Primary endpoint: Safety and tolerability. Started Nov 2016; status: terminated.
02
Drugs
DVC1-0101
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on ACTRN12615001144505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001144505.